Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Clusterin as a biomarker of cognition in mild cognitive impairment: exploring its role in exercise-primed transcranial direct current stimulation

FY 2024-25

Summary
Alzheimer's Disease (AD) is characterized by abnormal protein buildup which disrupts brain function by blocking the connections between neurons, known as synapses, and leads to cognitive decline. Currently, no treatments exist that are effective for a precursory stage of AD known as mild cognitive impairment (MCI), where individuals experience early signs of cognitive decline which can interfere with daily life. Therefore, there is a need for new treatments which can delay or slow the progression from MCI to AD. This research aims to explore an emerging approach, anodal transcranial direct current stimulation (atDCS), which is a non-invasive technique that may improve cognition by restoring and strengthening damaged synapses. When combined with an exercise primer that activates the brain, atDCS has the potential to slow or reverse cognitive decline in MCI. This study will investigate the role of clusterin (CLU), a protein which plays a role in promoting synapse growth, in atDCS intervention. Previous studies have shown that CLU can improve cognition in AD mouse models, suggesting it may contribute to neuroprotection against AD processes. This study will examine whether CLU levels in the blood are linked to cognitive performance, and will evaluate if CLU could be used as a marker to track how well people with MCI respond to exercise-primed atDCS. I propose that higher concentrations of CLU will be associated with greater cognition, and that individuals treated with exercise-primed atDCS will have higher levels of CLU and greater improvements in cognition compared to those who do not undergo atDCS. The findings from this study could provide valuable insights into new ways to improve brain health and offer potential early interventions for people at risk of developing AD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529897
Name
Schecter Julian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Clusterin as a biomarker of cognition in mild cognitive impairment: exploring its role in exercise-primed transcranial direct current stimulation
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alzheimer'S Disease; Biomarker; Blood; Clusterin; Cognition; Dementia; Direct Current Stimulation; Geriatrics; Memory
Abstract
Alzheimer's Disease (AD) is characterized by abnormal protein buildup which disrupts brain function by blocking the connections between neurons, known as synapses, and leads to cognitive decline. Currently, no treatments exist that are effective for a precursory stage of AD known as mild cognitive impairment (MCI), where individuals experience early signs of cognitive decline which can interfere with daily life. Therefore, there is a need for new treatments which can delay or slow the progression from MCI to AD. This research aims to explore an emerging approach, anodal transcranial direct current stimulation (atDCS), which is a non-invasive technique that may improve cognition by restoring and strengthening damaged synapses. When combined with an exercise primer that activates the brain, atDCS has the potential to slow or reverse cognitive decline in MCI. This study will investigate the role of clusterin (CLU), a protein which plays a role in promoting synapse growth, in atDCS intervention. Previous studies have shown that CLU can improve cognition in AD mouse models, suggesting it may contribute to neuroprotection against AD processes. This study will examine whether CLU levels in the blood are linked to cognitive performance, and will evaluate if CLU could be used as a marker to track how well people with MCI respond to exercise-primed atDCS. I propose that higher concentrations of CLU will be associated with greater cognition, and that individuals treated with exercise-primed atDCS will have higher levels of CLU and greater improvements in cognition compared to those who do not undergo atDCS. The findings from this study could provide valuable insights into new ways to improve brain health and offer potential early interventions for people at risk of developing AD.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Schecter, Julian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~